I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
Evan Jacob Lipson, M.D.
Associate Professor of Oncology
Specializes in: Adults (18+ years)
Expertise: Clinical Trials, Immunotherapy, Medical Oncology, Melanoma
Research Interests: Melanoma; Immunotherapy
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Sibley Memorial Hospital
Appointment Phone: 202-660-6500
5255 Loughboro Road, NW
Washington, DC 20016 map
Evan J. Lipson, M.D., is a medical oncologist at the Johns Hopkins Kimmel Cancer Center as well as an associate professor of oncology at the Johns Hopkins University School of Medicine. He sees patients in Baltimore and at Sibley Memorial Hospital in Washington, DC.
Dr. Lipson earned his undergraduate degree from the University of Maryland and his medical degree from the Mount Sinai School of Medicine. He completed a residency in internal medicine at the Johns Hopkins University School of Medicine, as well as a fellowship at Hopkins in medical oncology.
Dr. Lipson's clinical expertise is in the treatment of patients with advanced skin cancers, including melanoma, Merkel cell carcinoma, basal cell carcinoma, and skin squamous cell carcinoma, among others.
As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, Dr. Lipson focuses on evaluating novel therapies for patients with high-risk or advanced skin cancer. He is a principal or co-investigator on multiple trials, involving partners from both industry and academia, which focus on the clinical development of antibodies that block the PD-1/PD-L1 pathway. He is collaborating to develop new methods to predict and monitor their therapeutic effects, including nuclear imaging and serum-based molecular markers. Dr. Lipson’s publications include the first description of successful PD-1 re-induction therapy (Clin Can Res 2013), and the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer (JCO 2014, NEJM 2016).
Dr. Lipson is also an internationally-recognized educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs.
- Associate Professor of Oncology
Departments / Divisions
- Medicine at Sibley Memorial Hospital
- Oncology - Medical Oncology
Centers & Institutes
- MD, Mount Sinai School of Medicine (2005)
- Johns Hopkins University School of Medicine / Medicine (2008)
- Johns Hopkins University School of Medicine / Oncology (2011)
- American Board of Internal Medicine / Internal Medicine (2008)
- American Board of Internal Medicine / Medical Oncology (2010)
Research & Publications
View Dr. Lipson's current research trials at Sibley Memorial Hospital here.
Selected PublicationsView all on Pubmed
Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19:462-468.
Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016.
Lipson EJ, Bagnasco SM, Moore J,Jr, Jang S, Patel MJ, Zachary AA, Pardoll DM, Taube JM, Drake CG. Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. N Engl J Med. 2016;374:896-898.
Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol. 2014;32:e69-71.
Rowe SP, Luber B, Makell M, Brothers P, Santmyer J, Schollenberger MD, Quinn H, Edelstein DL, Jones FS, Bleich KB, Sharfman WH, Lipson EJ. From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol. 2018 Aug 16.
Activities & Honors
- Seize The Days
- Johns Hopkins Multidisciplinary Cancer Committee
- American Society for Clinical Oncology
- Society for Melanoma Research
- Society for Immunotherapy of Cancer
- Eastern Cooperative Oncology Group
Videos & Media
Recent News Articles and Media Coverage
New Cancer treatments have perplexing side effects, The Washington Post , Jan 2, 2018
How Does Immunotherapy Work?, Melanoma Research Alliance, Feb. 2, 2016
In The Beginning, Hopkins Medicine, Fall 2014
Keytruda Just One of a New Class of Cancer Drugs to Restart the Immune System, Healthline News, Sept. 10, 2014
New Skin Cancer Drug Approved, CNN, Jan. 31, 2012
'Seize the Days' Project Documents a Life with Cancer, WAMU 88.5, Jan. 6, 2012
Giving Patients a Way to Share Their Stories, Cancer.Net, April 4, 2011